Delta-8 THC Statistics (2026): Usage, Sales, Safety Data, and the Ban

In 2023, 11.4% of U.S. 12th graders reported using delta-8 THC in the past 12 months. That figure comes from Harlow, Miech, and Leventhal's analysis of the Monitoring the Future survey, published in JAMA in March 2024 (JAMA 2024;331(10):861-865) — a sample of 2,186 randomly selected 12th graders across 27 states, funded by the National Institute on Drug Abuse. It was the first national prevalence estimate for adolescent delta-8 use, and NIDA's own headline was blunt: delta-8 had only existed as a retail product since roughly 2018, and one in nine high-school seniors had used it within a year.

The follow-up data held steady. In the 2024 Monitoring the Future survey, 12.3% of 12th graders reported past-year delta-8 use — statistically unchanged from 2023, per NIDA's December 2024 release. That survey also measured younger grades for the first time: 2.9% of 8th graders and 7.9% of 10th graders reported past-year use. Two more precise findings from the JAMA analysis worth quoting correctly: roughly nine in ten 12th graders who used delta-8 also reported marijuana use (the two travel together, they don't substitute cleanly), and prevalence was about 14% in states without adult-use marijuana legalization versus 8% in states with it, and about 14% where delta-8 was unregulated versus 6% where states had their own delta-8 rules.

About 7.7% of U.S. adults (95% CI, 6.5-9.1) reported ever using delta-8 THC, per a national probability survey of 1,523 adults fielded October-November 2023 and published in the Journal of Cannabis Research (2025). For scale, the same survey put lifetime CBD use at 35.2%. So delta-8 was never a majority behavior; it was a sizable niche. When those researchers asked why people used it, the most common self-reported reasons were anxiety (18.6% of users), pain (15.2%), and insomnia (10.7%) — we report those as reasons users gave, not as evidence the products work for any of them, which no regulator has accepted.

The geography is the story. A UC San Diego-led analysis of the same survey, published in the American Journal of Preventive Medicine (2025), found adults in states that prohibit all marijuana were about twice as likely to have used delta-8 (10.9%) as adults in states with legal adult-use marijuana (roughly 5.5%). State delta-8 policy mattered even more: lifetime use was 10.5% where delta-8 sales were unregulated, versus 4.5% where they were banned and 3.9% where they were regulated. One earlier data point for the heaviest users: in a 2021 web-recruited sample of 4,348 past-30-day cannabis-using adults, 16.7% reported past-30-day delta-8 use (Addictive Behaviors, 2022) — a convenience sample, so treat it as directional, not national.

The pattern across teens and adults is the single most-replicated finding in delta-8 research: delta-8 filled the gaps in the legalization map. Where regulated marijuana existed, delta-8 demand was low. Where it didn't, gas stations sold the substitute.

Market numbers for an unregulated category are estimates, and the honest move is to name the firm and the definition every time. The most-cited transaction-based figures come from Brightfield Group: delta-8 products generated roughly $2 billion in U.S. retail sales across 2021 and 2022 combined (reported January 2023), and in 2023 delta-8 sales were about $1.2 billion — around 44% of the intoxicating hemp-derived cannabinoid market, which Brightfield sized near $2.8 billion for 2023, up roughly 1,283% from $200.5 million in 2020 (via Cannabis Business Times).

Yes, those top and bottom rows differ by an order of magnitude. Brightfield counts tracked retail transactions in the intoxicating-product niche; Whitney Economics models total demand across the entire hemp-derived cannabinoid economy, CBD included, plus employment. Neither is wrong; they measure different things. If you quote a delta-8 market size without naming the firm and the definition, you are, statistically speaking, making it up.

Framing first, because this is where adversarial readers live: poison-center figures count reports of exposure — calls and cases logged by America's Poison Centers member centers — not confirmed poisonings, injuries, or product defects. With that said, the peer-reviewed record is specific. From January 1, 2021 through December 31, 2022, U.S. poison centers received 4,925 exposure reports involving delta-8 THC as the primary substance, rising 82.1% from 1,746 cases in 2021 to 3,179 in 2022 (Smith et al., Journal of Medical Toxicology, 2024, analyzing National Poison Data System records; the study team was based at Nationwide Children's Hospital).

The age distribution is the part that moved regulators. Nearly one in three reported exposures (about 30%) involved children under 6, and children under 6 accounted for 58% of critical-care admissions in the dataset. Geography repeated the usage pattern: the South accounted for 69.8% of reported exposures, with Alabama posting the highest 2022 state rate (3.35 reports per 100,000 residents). And policy tracked with reports the same way it tracked with use: states that banned delta-8 logged 0.17 exposures per 100,000 versus 1.36 in unregulated states, and legal-marijuana states logged 0.52 versus 1.64 in prohibition states. The FDA's own earlier tally, covering January 1, 2021 through February 28, 2022, counted 2,362 delta-8 exposure cases, 41% involving patients under 18; 40% were unintentional exposures, and 82% of the unintentional cases involved children.

The FDA runs its own adverse-event pipeline, separate from poison centers, and its delta-8 consumer update ("5 Things to Know about Delta-8 Tetrahydrocannabinol") is the primary source. Between December 1, 2020 and February 28, 2022, the FDA received 104 adverse-event reports involving delta-8 products; 77% involved adults, and 55% required intervention such as EMS evaluation or hospital admission. Reported effects included hallucinations, vomiting, tremor, anxiety, dizziness, confusion, and loss of consciousness. By October 31, 2023, the cumulative count had passed 300 reports in children and adults.

Same discipline applies: an adverse-event report is a report — unverified, not proof of causation, and dependent on who bothers to file. The counts are real and worth citing; what they prove is contested, and an honest data page says both halves. What the numbers unambiguously supported was the FDA's position that delta-8 products had never been evaluated or approved for any use, and that a market with no dosing, packaging, or manufacturing standards was generating a growing pile of reports involving kids.

The most-cited product-testing study of the delta-8 era was commissioned by the review site CBD Oracle in 2021, with the lab work done by FESA Labs on 51 of the best-selling hemp-derived delta-8 products. The findings, precisely: 76% of the 51 products exceeded the 0.3% delta-9 THC limit that made them nominally legal hemp, with an average delta-9 content of 6.6% — roughly 22 times the limit — and one vape reaching 23% delta-9, about 7,700% of the legal ceiling. Of the 41 products that stated a measurable delta-8 quantity on the label or an accompanying COA, 77% contained less delta-8 than advertised. Two published COAs showed signs of alteration, and only 16% of the companies used substantial age verification at checkout.

Attribution matters here: this was an industry-commissioned study of one purchased sample per product, not a peer-reviewed survey of the whole market — and it is still the best public snapshot of what was actually inside the packages. Its practical takeaway aged perfectly: in an unregulated category, the label was a suggestion. That finding, more than any usage statistic, is what both state regulators and Congress ended up citing.

By the time Congress acted, a patchwork of states already had. The Marijuana Policy Project's delta-8 tracker lists 14 states that fully prohibited delta-8 sales (Alaska, Arizona, Colorado, Delaware, Idaho, Iowa, Montana, Nevada, New York, North Dakota, Rhode Island, Utah, Vermont, Washington) plus roughly 8 more that regulated or restricted it — about 20-plus states in total, with industry trackers counting as high as 17 outright bans depending on how you classify dispensary-only rules. The counts genuinely vary by classification method, which is why we name the tracker.

Federal enforcement before the ban was warning letters, in three documented rounds: May 2022, the FDA's first-ever delta-8 letters, to 5 companies for unapproved drug claims and related violations; July 2023, FDA and FTC jointly warned 6 companies selling delta-8 edibles in copycat packaging mimicking children's snacks (Froot Loops, Chips Ahoy, Skittles, and similar); and July 2024, a second joint FDA/FTC round of cease-and-desist letters over child-appealing packaging. Add the enforcement math up and it explains the legislative outcome: a multibillion-dollar intoxicating market, a 300-report FDA docket, thousands of pediatric poison-center reports, and a federal toolkit limited to strongly worded letters.

The end arrived as four numbers inside an appropriations bill. On November 12, 2025, the full-year FY2026 Agriculture appropriations act (P.L. 119-37, Division B, Section 781) rewrote the federal definition of hemp in 7 U.S.C. 1639o, per the Congressional Research Service: (1) the 0.3% threshold now counts total THC, not just delta-9; (2) finished hemp-derived cannabinoid products are excluded from the hemp definition if they contain more than 0.4 milligrams of THC per container; (3) cannabinoids synthesized or manufactured outside the plant are excluded entirely — and commercial delta-8 is made by chemically converting hemp CBD, which is precisely this; and (4) the new definition takes effect November 12, 2026, one year after enactment.

For delta-8 the synthesis exclusion is the decisive clause: it doesn't cap delta-8, it defines delta-8 products out of "hemp" and back into the Controlled Substances Act's marijuana definition. The U.S. Hemp Roundtable, the industry's own trade group, estimates roughly 95% of today's hemp cannabinoid products can't meet the new definition. The honest caveats, dated: repeal and delay bills exist (including the American Hemp Protection Act of 2025), the April 2026 House Farm Bill passed without delaying the ban, and CRS itself notes it is unclear how aggressively FDA and DEA will enforce against products that linger. As it stands on July 1, 2026, the date is real, and this page will read as a statistical portrait of a category with about four months to live. Our full plain-English guide to what survives is here.

Three habits keep delta-8 stats honest. Name the population and the year: "11.4% of 12th graders, past-year, 2023, Monitoring the Future via JAMA" is bulletproof; "1 in 9 teens vape delta-8" is not (the survey asked about any use, not vaping). Keep reports and harms separate: 4,925 poison-center cases and 300+ FDA reports are counts of reports, and the sources themselves say so. Name the firm on any market number, because the honest range spans $1.2 billion (Brightfield, delta-8 retail, 2023) to $28 billion (Whitney Economics, all hemp cannabinoid demand) depending on definition.

Everything on this page is dated, sourced, and free to reproduce with the sourcing intact. It is general information, not medical or legal advice; delta-8's legal status varies by state today and changes federally on November 12, 2026, as it stands now. We update this page as the primary sources do.